Neglected Tropical Diseases key aspects for the rheumatologist
Main Article Content
Abstract
Neglected tropical diseases (NTDs) are a group of 20 infectious diseases that are no longer restricted to tropical regions and that will be increasingly encountered by physicians of the Northern hemisphere.
In this article, we review key aspects of tropical medicine relevant for rheumatologists or doctors working with autoimmune diseases or immunosuppressive drugs in order to be aware of NTDs, look out for them and prevent their complications.
The article addresses four main topics:
- eosinophilia workup,
- rheumatic presentations of NTDs, such as myositis or arthritis
- lupus, granulomatosis with polyangiitis or vasculitis mimickers, such Leishmaniasis, Leprosy or Human African Trypanosomiasis and
- screening before starting immunosuppression, including Strongyloidiasis and Chagas disease
With this review, we intend to raise awareness for NTDs amongst rheumatologists and internists working in the Northern hemisphere. NTDs should be considered and excluded in patients with relevant travelhistory or exposure in following situations:
- during the differential diagnosis of a suspected new autoimmune condition,
- in case of poor response or flare of symptoms on initiating immunosuppressive therapy,
- during systematic screening prior to starting immunosuppressive medication, along with blood born viruses and tuberculosis.
Article Details
How to Cite
LE GOUEFF, Anouk et al.
Neglected Tropical Diseases key aspects for the rheumatologist.
Medical Research Archives, [S.l.], v. 11, n. 12, jan. 2024.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/4512>. Date accessed: 15 may 2024.
doi: https://doi.org/10.18103/mra.v11i12.4512.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. The Lancet. Neglected tropical diseases: becoming less neglected. Lancet 2014;383(9925):1269.
2. Holmes P. Neglected tropical diseases in the post-2015 health agenda. Lancet 2014;383(9925):1803.
3. O'Connell EM, Nutman TB. Eosinophilia in Infectious Diseases. Immunol Allergy Clin North Am 2015;35(3):493–522.
4. Neglected tropical diseases: no longer someone else's problem. Lancet Infect Dis. 2014;14(10):899.
5. Seventh Meeting of the Working Group on Health in Climat Change (HIC) of the European Environment and Health Task Force. Bonn: World Health Organization; 2019 (https://www.euro.who.int/__data/assets/pdf_file/0004/440338/7th-meeting-Health-in-Climate-Change-HIC.pdf).
6. Fabiani S, Bruschi F. Rheumatological patients undergoing immunosuppressive treatments and parasitic diseases: A review of the literature of clinical cases and perspectives to screen and follow-up active and latent chronic infections. Clin Exp Rheumatol 2014;32 :587-596.
7. Zammarchi L, Gobbi F, Bartoloni A et al. Schistosomiasis, strongyloidiasis and Chagas disease: the leading imported neglected tropical diseases in Italy. J Travel Med 2020;27(1):taz100
8. Public health and climate change adaptation policies in the European Union – final report. Geneva: World Health Organization; 2018 (https://www.euro.who.int/__data/assets/pdf_file/0010/386965/Pagoda-REPORT-final-published-2.pdf).
9. Climate change data and statistics. Geneva: World Health Organization (http://www.euro.who.int/en/health-topics/environment-and-health/Climate-change/data-and-statistics, accessed 09 August 2020)
10. Climate change and health. Geneva: World Health Organization; 2017 (https://www.who.int/mediacentre/factsheets/fs266/en/, accessed 09 August 2020).
11. Manual on management and surveillance of the leishmaniases in the WHO European Region. Geneva: World Health Organization; 2017 (https://www.who.int/leishmaniasis/resources/EURO_WHO_Leish_manual_on_case_management_and_surveillance_9789289052511_2017.pdf?ua=1).
12. Romero Alegría A, Hernández Cabrera, Pérez Arellano JL, et al. Fake imported tropical diseases: A retrospective study. Rev Esp Quimioter 2018;31(6):528-531.
13. Statistics Canada. Table 17-10-0008-01 Estimates of the components of demographic growth, annual ; 2021 (https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000801, accessed 13 September 2021).
14. U.S. Department of Homeland Security. Table 20. Petitions for Naturalization Filed, Persons Naturalized, and Petitions for Naturalization Denied: Fiscal Years 1908 to 2019; 2020 (https://www.dhs.gov/immigration-statistics/yearbook/2019/table20, accessed 13 September 2021).
15. Migration and migrant population statistics. Eurostat 2020 (https://ec.europa.eu/eurostat/statistics-explained/index.php/Migration_and_migrant_population_statistics#Acquisitions_of_citizenship:_EU-27_Member_States_granted_citizenship_to_672_thousand_persons_in_2018, accessed 09 August 2020).
16. Keystone JS. Chapter 9 - Visiting Friends & Relatives. Centers for Disease Control and Prevention; 2020 (https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-for-work-other-reasons/visiting-friends-and-relatives-vfr-travel, accessed 09 August 2020)
17. Migration Data Portal. (https://migrationdataportal.org/?i=stock_abs_&t=2019, accessed 09 August 2020).
18. Seedat F, Hargreaves S, Friedland JS, et al. How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review. Lancet Infect Dis 2018;18:259–271.
19. Cinardo P, Farrant O, Gunn K, Ward A, Eisen S, Longley N. Screening for neglected tropical diseases and other infections in refugee and asylum-seeker populations in the United Kingdom. Ther Adv Infect Dis 2022 ;9:20499361221116680.
20. Leishmaniasis. Geneva: World Health Organization; 2020 (https://www.who.int/health-topics/leishmaniasis, accessed 09 August 2020).
21. Leprosy (Hansen’s disease. Geneva: World Health Organization; 2020 (https://www.who.int/health-topics/leprosy, accessed 09 august 2020).
22. Chagas disease (also known as American trypanosomiasis. Geneva: World Health Organization; 2020 (https://www.who.int/en/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis), accessed 09 august 2020).
23. Salvador F, Sánchez-Montalvá A, Valerio L, Molina I, et al. Immunosuppression and Chagas disease; experience from a non-endemic country. Clin Microbiol Infect 2015;21(9):854-860.
24. Salas-Coronas J, Ramírez-Olivencia G, Muñoz J, et al. Diagnosis and treatment of imported eosinophilia in travellers and immigrants: Recommendations of the Spanish Society of Tropical Medicine and International Health (SEMTSI). Rev Esp Quimioter 2016; 30(1):62-78.
25. Valent P, Klion AD, Gleich GJ, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012;130(3):607-612.
26. Barrett J, Warrell CE, Whitty CJM, et al. The changing aetiology of eosinophilia in migrants and returning travellers in the Hospital for Tropical Diseases, London 2002-2015: An observational study. J Infect 2017;75(4):301-308.
27. Bartalesi F, Scirè C, Requena-Méndez A, et al. Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants today. Clin Exp Rheumatol. 2017;35(5):752-765.
28. Fairley JK. Chapter 11 – General approach to the returned traveller. Centers for Disease Control and Prevention; 2020 (https://wwwnc.cdc.gov/travel/yellowbook/2020/posttravel-evaluation/general-approach-to-the-returned-traveler, accessed 09 August 2020).
29. Misra DP, Sharma A, Agarwal V. Rheumatology science and practice in India. Rheumatol Int. 2018;38(9):1587-1600.
30. Alpay-Kanıtez N, Çelik S, Bes C. Polyarthritis and its differential diagnosis. Eur J Rheumatol 2018;6(4):167-173.
31. Mathew AJ, Ravindran V. Infections and arthritis. Best Pract Res Clin Rheumatol 2014;28(6):935-959.
32. Shu Kurizky P, Dos Santos Neto LL, Martins Gomes C, et al. Opportunistic tropical infections in immunosuppressed patients. Best Pract Res Clin Rheumatol 2020;101509.
33. Adizie T, Adebajo AO. Travel- and immigration-related problems in rheumatology. Best Pract Res Clin Rheumatol 2014;28(6):973-985.
34. Sixdorf U, Märker-Hermann E. Viral Arthritis and vasculitis. Z Rheumatol 2016;75(9):878-884.
35. Peng S. Rheumatic manifestations of parasitic diseases. Semin Arthritis Rheum 2002;31:228-47.
36. Amaral JK, Bilsborrow JB, Schoen RT. Chronic Chikungunya Arthritis and Rheumatoid Arthritis: What They Have in Common. Am J Med 2020;133(3):e91-e97.
37. Pathak H, Mohan MC, Ravindran V. Chikungunya arthritis. Clin Med (Lond) 2019;19(5):381-385.
38. Zias J, Mitchell P. Psoriatic arthritis in a fifth-century Judean Desert monastery. Am J Phys Anthropol 1996;101(4):49-502.
39. El-Beshbishi S, Bardicy S, Taman A, et al. Parasitic infections and myositis. Parasitol Res 2012;110:1–18.
40. Molina B, Pogossian A, Le Berre R, et al. Infectious myositis. Rev Med Interne 2020;41(4):241-249.
41. Aringer M. EULAR/ACR classification criteria for SLE. Semin Arthritis Rheum 2019;49(3S):14-17.
42. Tsokos GC. Systemic Lupus Erythematosus. N Engl J Med 2011; 365:2110-2121.
43. Van Griensven J, Carrillo E, Moreno J, et al. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 2014;20(4):286-299.
44. Illescas-Montes R, Corona-Castro CC, Costela-Ruiz VJ, et al. Infectious processes and systemic lupus erythematosus. Immunology 2019;158(3):153-160.
45. Chauhan S, Wakhlu A, Agarwal V. Arthritis in leprosy. Rheumatology (Oxford, England);49:2237-42.
46. Fletcher K, Issa R, Lockwood DN. Visceral leishmaniasis and immunocompromise as a risk factor for the development of visceral leishmaniasis: a changing pattern at the hospital for tropical diseases, London. PLoS One 2015;10:e0121418.
47. Santana IU, Dias B, Santiago MB, et al. Visceral leishmaniasis mimicking systemic lupus erythematosus: case series and a systematic literature review. Semin Arthritis Rheum 2015; 44:658–65.
48. WHO guidelines for diagnosis, treatment and prevention of leprosy. Geneva: World Health Organization; 2018 (http://apps.who.int/iris/bitstream/handle/10665/274127/9789290226383-eng.pdf).
49. Reibel F, Chauffour A, Aubry A, et al. New Insights into the Geographic Distribution of Mycobacterium leprae SNP Genotypes Determined for Isolates from Leprosy Cases Diagnosed in Metropolitan France and French Territories. PLoS Negl Trop Dis 2015;9(10):e0004141.
50. Norman F, Fanciulli C, López-Vélez R, et al. Imported and autochthonous leprosy presenting in Madrid (1989-2015): A case series and review of the literature. Travel Med Infect Dis 2016;14:331-349.
51. Prasad S, Misra R, Aggarwal A, et al. Leprosy revealed in a rheumatology clinic: a case series. Int J Rheum Dis 2013;16:129–133.
52. Baharuddin H, Taib T, Zain MM, Ch'ng S. Leprae reaction resembling rheumatologic disease as presenting feature of leprosy. Int J Rheum Dis 2016;19(10):1035-1038.
53. Ribeiro FM, Gomez VE, Shoenfeld Y, et al. Lupus and leprosy: beyond the coincidence. Immunol Res 2015;61(1-2):160-163.
54. Junior G, Elis E, Magalhães V. Application of the diagnostic criteria for systemic lupus erythematosus to patients with multibacillary leprosy. Rev Soc Bras Med Trop 2011;44:85-90.
55. Horta-Baas G, Hernandez-Cabrera MF, Arenas-Guzman R, et al. Multibacillary leprosy mimicking systemic lupus erythematosus: case report and literature review. Lupus 2015;24(10):1095–102.
56. Labuda SM, Schieffelin JS, Shaffer JG, Stryjewska BM. Hansen's Disease and Rheumatoid Arthritis Crossover of Clinical Symptoms: A Case Series of 18 Patients in the United States. Am J Trop Med Hyg 2017;97(6):1726-1730.
57. Hsieh TT, Wu YH. Leprosy mimicking lupus erythematosus. Dermatol Sin 2014:32(1):47-50.
58. Karadeniz A, Lally L, Lockshin MD, et al. Lepromatous Leprosy Mimicking Systemic Lupus Erythematosus. HSS J 2014;10(3):286-291.
59. Garg G, Gogia A, Kakar A. Leprosy: A Great Mimicking Disease. Indian J Lepr 2016;88(2):123-127
60. Kusumaningrum N, Purnamawati S, Soebono H, et al. Lepromatous leprosy mimicking systemic lupus erythematosus: a case report. Med J Indones 2019;28(1):77-1.
61. African Trypanosomiasis. Geneva: World Health Organization; 2020 (http://www.who.int/topics/trypanosomiasis_african/en, accessed 09 August 2020).
62. Meltzer E, Leshem E, Steinlauf S, et al. Human African trypanosomiasis in a traveler: diagnostic pitfalls. Am J Trop Med Hyg 2012;87(2):264-266.
63. Sudarshi D, Brown M. Human African trypanosomiasis in non-endemic countries. Clin Med 2015;15(1):70-73.
64. Guillaume MP, Hermanus N, Karmali R, et al. Specific autoantibodies of SLE, such as anti-Ku, anti-ribosome Po and anti-membrane DNA autoantibodies, in a case of human African trypanosomiasis. Rheumatology 2003 ;42(12) :1568–1569.
65. Kirrstetter M, Lerin-Lozano C, Lamprecht P, et al. Trypanosomiasis in a woman from Cameroon mimicking systemic lupus erythematosus]. Dtsch Med Wochenschr 2004;129(23):1315-1317.
66. Leavitt RY, Fauci AS, Lightfoot RW, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33(8):1101.
67. Robson JC, Grayson PC, Ponte C, DCVAS Investigators, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 2022;81(3):315-320.
68. Guntupalli L, Patel K, Faraji F, Brunworth JD. Autoimmune-related nasal septum perforation: A case report and systematic review. Allergy Rhinol 2017;8(1):40-44.
69. Montone KT. The molecular genetics of inflammatory, autoimmune, and infectious diseases of the sinonasal tract: a review. Arch Pathol Lab Med 2014;138(6):745-753.
70. Laudien M. Orphan diseases of the nose and paranasal sinuses: Pathogenesis - clinic - therapy. GMS Curr Top Otorhinolaryngol Head Neck Surg 2015;14:Doc04.
71. Sachse F, Stoll W. Nasal surgery in patients with systemic disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc02.
72. Alam E, Abbas O, Moukarbel R, Khalifeh I. Cutaneous Leishmaniasis: An Overlooked Etiology of Midfacial Destructive Lesions. PLoS Negl Trop Dis 2016;10(2):e0004426.
73. Edington FL, Bacellar MO, Machado PR, et al. Anti-neutrophil cytoplasmic antibodies in leprosy. Clin Rheumatol 2007;26(2):208-210.
74. Camacho ID, Burdick A, Benjamin L, Casiano R. Chronic rhinitis: a manifestation of leprosy. Ear Nose Throat J 2011;90(9):E1-E3.
75. Kim JH, Lee OJ, Lee JJ, Park CH. Analysis of facial deformities in korean leprosy. Clin Exp Otorhinolaryngol 2013;6(2):78-81.
76. Crovetto-Martínez, R, Aguirre-Urizar JM, Torre CD, et al. Mucocutaneous leishmaniasis must be included in the differential diagnosis of midline destructive disease: Two case reports. OOOO Journal 2014;119(1):20-26.
77. Bhat R, Sharma VK, Deka RC. Otorhinolaryngologic manifestations of leprosy. Int J Dermatol 2007;46(6):600-606.
78. Martins AC, Castro JC, Moreira JS. A ten-year historic study of paranasal cavity endoscopy in patients with Leprosy. Braz J Otorhinolaryngol 2005;71(5):609-615.
79. Taheri JB, Mortazavi H, Moshfeghi M, et al. Oro-facial manifestations of 100 leprosy patients. Med Oral Patol Oral Cir Bucal. 2012;17(5):728-732.
80. Pooja VK, Vanishree M, Surekha R, et al. Evaluation of the orofacial lesions in treated leprosy patients. J Oral Maxillofac Pathol 2014;18(3):386-389.
81. Lockwood D. Recognizing Leprosy: Pointers for the Busy Rheumatologist. Rheumatology 2014;53:i12.
82. Wall EC, Watson J, Lockwood DN, et al. Epidemiology of imported cutaneous leishmaniasis at the Hospital for Tropical Diseases, London, United Kingdom: use of polymerase chain reaction to identify the species. Am J Trop Med Hyg 2012;86(1):115-8.
83. Bart A, Thiel PP, Van Gool T, et al. Imported leishmaniasis in the Netherlands from 2005 to 2012: epidemiology, diagnostic techniques and sequence-based species typing from 195 patients. Euro Surveill 2013;18(30)205-44.
84. Antunes ML, Cabral G, Araújo J, et al. Going Round in Circles with a Multisystemic Disease: A Unique Case of Parasitic Aortitis. Eur J Case Rep Intern Med 2017;4(6):000601.
85. Chauhan A, Scott DGI, Neuberger J, et al. Churg–Strauss vasculitis and ascaris infection. Ann Rheum Dis 1990;49:320–322.
86. Pandey S, Nayak R, Mehndiratta MM. Hansen's disease manifesting as acute distal symmetric microvasculitic polyneuropathy. Clin Neurol Neurosurg 2013;115(10):2223-2225.
87. Sampaio L, Silva L, Terroso G, et al. Hansen's disease mimicking a systemic vasculitis. Acta Reumatol Port 2011;36(1):61-64.
88. Sadeghinia A, Azizzadeh-Roodpishi S, Mahmoudi H, et al. A Case of Lepromatous Leprosy Clinically Masquerading as Vasculitis. Dermatol Pract Concept 2019;9(3):222-224.
89. Pawar M, Zawar V. Mid-borderline leprosy masquerading as an overlap syndrome. Rheumatology 2018 ;57(9):1686–1688.
90. Gupta L, Zanwar A, Wakhlu A, Agarwal V. Leprosy in the rheumatology clinic: an update on this great mimic. Int J Rheum Dis 2016;19(10):941–5.
91. Lee JY, Park SE, Kim SS, et al. Case of lepromatous leprosy misdiagnosed as systemic sclerosis. J Dermatol 2014;41(4):343–5.
92. Pruthi P, Munganda H, Brajpuriya S, et al. Case Report Leprosy with Atypical Skin Lesions Masquerading as Relapsing Polychondritis. Case Rep Infect Dis 2016;2016:7802423.
93. Yusuf SYM, Ismail IA, Yasin MM, et al. Isolated Bilateral Pinna Swelling: A Rare Initial Presentation of Leprosy. Open Access Maced J Med Sci 2019;7(11):1815-1817.
94. Deligny C, Arfi S. Images in clinical tropical medicine. Pseudochondritis in leprosy. Am J Trop Med Hyg 2010;83(6):1175.
95. Levy M, Bourrat E, Fila M, et al. Toxocara canis infection: Unusual trigger of systemic lupus erythematosus. Ped Intern 2015;57(4):785-788.
96. De Boysson H, et al. Vasculitis Secondary to anti-C1q Antibodies Induced By Toxocariasis. Infection 2015 ;43(6) :755-8.
97. Kotton CN. Chapter 5 - Immunocompromised travellers. Centers for Disease Control and Prevention; 2019 (https://wwwnc.cdc.gov/travel/yellowbook/2020/travelers-with-additional-considerations/immunocompromised-travelers, accessed 09 August 2020).
98. Braz AS, de Andrade CA, Da Mota LM, Lima CM. Recommendations from the Brazilian Society of Rheumatology on the diagnosis and treatment of intestinal parasitic infections in patients with autoimmune rheumatic disorders. Rev Bras Reumatol 2015;55:368-80.
99. Libman L, Barkati S. Chapter 11 – Screening asymptomatic returned travellers. Centers for Disease Control and Prevention ; 2019 (https://wwwnc.cdc.gov/travel/yellowbook/2020/posttravel-evaluation/screening-asymptomatic-returned-travelers, accessed 09 August 2020).
100. Refugee Health guidelines. Centers for Disease Control and Prevention; 2020 (https://www.cdc.gov/immigrantrefugeehealth/guidelines/refugee-guidelines.html, accessed 09 August 2020).
101. Krolewiecki A, Nutman TB. Strongyloidiasis: A Neglected Tropical Disease. Infect Dis Clin North Am 2019;33(1):135-151.
102. Requena-Méndez A, Buonfrate D, Muñoz J, et al. Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries. Am J Trop Med Hyg 2017;97(3):645-652.
103. Boggild AK, Libman M, Greenaway C, McCarthy AE. CATMAT statement on disseminated strongyloidiasis: prevention, assessment and management guidelines. Can Commun Dis Rep 2016;42:12-19
104. Agbata EN, Morton RL, Bisoffi Z, et al. Effectiveness of Screening and Treatment Approaches for Schistosomiasis and Strongyloidiasis in Newly-Arrived Migrants from Endemic Countries in the EU/EEA: A Systematic Review. Int J Environ Res Public Health 2018;16(1):11.
105. Velasco M, Gimeno-Feliú LA, Molina I, et al. Screening for Trypanosoma cruzi infection in immigrants and refugees: Systematic review and recommendations from the Spanish Society of Infectious Diseases and Clinical Microbiology. Euro Surveill 2020;25(8):1900393.
106. Salvador F, Sánchez-Montalvá A, Sulleiro E, et al. Prevalence of Chagas Disease among Solid Organ-Transplanted Patients in a Nonendemic Country. Am J Trop Med Hyg 2018;98(3):742-746.
107. Pinazo MJ, Espinosa G, Cortes-Lletget C, et al. Immunosuppression and Chagas disease: a management challenge. PLoS Negl Dis 2013;7:e1965.
2. Holmes P. Neglected tropical diseases in the post-2015 health agenda. Lancet 2014;383(9925):1803.
3. O'Connell EM, Nutman TB. Eosinophilia in Infectious Diseases. Immunol Allergy Clin North Am 2015;35(3):493–522.
4. Neglected tropical diseases: no longer someone else's problem. Lancet Infect Dis. 2014;14(10):899.
5. Seventh Meeting of the Working Group on Health in Climat Change (HIC) of the European Environment and Health Task Force. Bonn: World Health Organization; 2019 (https://www.euro.who.int/__data/assets/pdf_file/0004/440338/7th-meeting-Health-in-Climate-Change-HIC.pdf).
6. Fabiani S, Bruschi F. Rheumatological patients undergoing immunosuppressive treatments and parasitic diseases: A review of the literature of clinical cases and perspectives to screen and follow-up active and latent chronic infections. Clin Exp Rheumatol 2014;32 :587-596.
7. Zammarchi L, Gobbi F, Bartoloni A et al. Schistosomiasis, strongyloidiasis and Chagas disease: the leading imported neglected tropical diseases in Italy. J Travel Med 2020;27(1):taz100
8. Public health and climate change adaptation policies in the European Union – final report. Geneva: World Health Organization; 2018 (https://www.euro.who.int/__data/assets/pdf_file/0010/386965/Pagoda-REPORT-final-published-2.pdf).
9. Climate change data and statistics. Geneva: World Health Organization (http://www.euro.who.int/en/health-topics/environment-and-health/Climate-change/data-and-statistics, accessed 09 August 2020)
10. Climate change and health. Geneva: World Health Organization; 2017 (https://www.who.int/mediacentre/factsheets/fs266/en/, accessed 09 August 2020).
11. Manual on management and surveillance of the leishmaniases in the WHO European Region. Geneva: World Health Organization; 2017 (https://www.who.int/leishmaniasis/resources/EURO_WHO_Leish_manual_on_case_management_and_surveillance_9789289052511_2017.pdf?ua=1).
12. Romero Alegría A, Hernández Cabrera, Pérez Arellano JL, et al. Fake imported tropical diseases: A retrospective study. Rev Esp Quimioter 2018;31(6):528-531.
13. Statistics Canada. Table 17-10-0008-01 Estimates of the components of demographic growth, annual ; 2021 (https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000801, accessed 13 September 2021).
14. U.S. Department of Homeland Security. Table 20. Petitions for Naturalization Filed, Persons Naturalized, and Petitions for Naturalization Denied: Fiscal Years 1908 to 2019; 2020 (https://www.dhs.gov/immigration-statistics/yearbook/2019/table20, accessed 13 September 2021).
15. Migration and migrant population statistics. Eurostat 2020 (https://ec.europa.eu/eurostat/statistics-explained/index.php/Migration_and_migrant_population_statistics#Acquisitions_of_citizenship:_EU-27_Member_States_granted_citizenship_to_672_thousand_persons_in_2018, accessed 09 August 2020).
16. Keystone JS. Chapter 9 - Visiting Friends & Relatives. Centers for Disease Control and Prevention; 2020 (https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-for-work-other-reasons/visiting-friends-and-relatives-vfr-travel, accessed 09 August 2020)
17. Migration Data Portal. (https://migrationdataportal.org/?i=stock_abs_&t=2019, accessed 09 August 2020).
18. Seedat F, Hargreaves S, Friedland JS, et al. How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review. Lancet Infect Dis 2018;18:259–271.
19. Cinardo P, Farrant O, Gunn K, Ward A, Eisen S, Longley N. Screening for neglected tropical diseases and other infections in refugee and asylum-seeker populations in the United Kingdom. Ther Adv Infect Dis 2022 ;9:20499361221116680.
20. Leishmaniasis. Geneva: World Health Organization; 2020 (https://www.who.int/health-topics/leishmaniasis, accessed 09 August 2020).
21. Leprosy (Hansen’s disease. Geneva: World Health Organization; 2020 (https://www.who.int/health-topics/leprosy, accessed 09 august 2020).
22. Chagas disease (also known as American trypanosomiasis. Geneva: World Health Organization; 2020 (https://www.who.int/en/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis), accessed 09 august 2020).
23. Salvador F, Sánchez-Montalvá A, Valerio L, Molina I, et al. Immunosuppression and Chagas disease; experience from a non-endemic country. Clin Microbiol Infect 2015;21(9):854-860.
24. Salas-Coronas J, Ramírez-Olivencia G, Muñoz J, et al. Diagnosis and treatment of imported eosinophilia in travellers and immigrants: Recommendations of the Spanish Society of Tropical Medicine and International Health (SEMTSI). Rev Esp Quimioter 2016; 30(1):62-78.
25. Valent P, Klion AD, Gleich GJ, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012;130(3):607-612.
26. Barrett J, Warrell CE, Whitty CJM, et al. The changing aetiology of eosinophilia in migrants and returning travellers in the Hospital for Tropical Diseases, London 2002-2015: An observational study. J Infect 2017;75(4):301-308.
27. Bartalesi F, Scirè C, Requena-Méndez A, et al. Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants today. Clin Exp Rheumatol. 2017;35(5):752-765.
28. Fairley JK. Chapter 11 – General approach to the returned traveller. Centers for Disease Control and Prevention; 2020 (https://wwwnc.cdc.gov/travel/yellowbook/2020/posttravel-evaluation/general-approach-to-the-returned-traveler, accessed 09 August 2020).
29. Misra DP, Sharma A, Agarwal V. Rheumatology science and practice in India. Rheumatol Int. 2018;38(9):1587-1600.
30. Alpay-Kanıtez N, Çelik S, Bes C. Polyarthritis and its differential diagnosis. Eur J Rheumatol 2018;6(4):167-173.
31. Mathew AJ, Ravindran V. Infections and arthritis. Best Pract Res Clin Rheumatol 2014;28(6):935-959.
32. Shu Kurizky P, Dos Santos Neto LL, Martins Gomes C, et al. Opportunistic tropical infections in immunosuppressed patients. Best Pract Res Clin Rheumatol 2020;101509.
33. Adizie T, Adebajo AO. Travel- and immigration-related problems in rheumatology. Best Pract Res Clin Rheumatol 2014;28(6):973-985.
34. Sixdorf U, Märker-Hermann E. Viral Arthritis and vasculitis. Z Rheumatol 2016;75(9):878-884.
35. Peng S. Rheumatic manifestations of parasitic diseases. Semin Arthritis Rheum 2002;31:228-47.
36. Amaral JK, Bilsborrow JB, Schoen RT. Chronic Chikungunya Arthritis and Rheumatoid Arthritis: What They Have in Common. Am J Med 2020;133(3):e91-e97.
37. Pathak H, Mohan MC, Ravindran V. Chikungunya arthritis. Clin Med (Lond) 2019;19(5):381-385.
38. Zias J, Mitchell P. Psoriatic arthritis in a fifth-century Judean Desert monastery. Am J Phys Anthropol 1996;101(4):49-502.
39. El-Beshbishi S, Bardicy S, Taman A, et al. Parasitic infections and myositis. Parasitol Res 2012;110:1–18.
40. Molina B, Pogossian A, Le Berre R, et al. Infectious myositis. Rev Med Interne 2020;41(4):241-249.
41. Aringer M. EULAR/ACR classification criteria for SLE. Semin Arthritis Rheum 2019;49(3S):14-17.
42. Tsokos GC. Systemic Lupus Erythematosus. N Engl J Med 2011; 365:2110-2121.
43. Van Griensven J, Carrillo E, Moreno J, et al. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 2014;20(4):286-299.
44. Illescas-Montes R, Corona-Castro CC, Costela-Ruiz VJ, et al. Infectious processes and systemic lupus erythematosus. Immunology 2019;158(3):153-160.
45. Chauhan S, Wakhlu A, Agarwal V. Arthritis in leprosy. Rheumatology (Oxford, England);49:2237-42.
46. Fletcher K, Issa R, Lockwood DN. Visceral leishmaniasis and immunocompromise as a risk factor for the development of visceral leishmaniasis: a changing pattern at the hospital for tropical diseases, London. PLoS One 2015;10:e0121418.
47. Santana IU, Dias B, Santiago MB, et al. Visceral leishmaniasis mimicking systemic lupus erythematosus: case series and a systematic literature review. Semin Arthritis Rheum 2015; 44:658–65.
48. WHO guidelines for diagnosis, treatment and prevention of leprosy. Geneva: World Health Organization; 2018 (http://apps.who.int/iris/bitstream/handle/10665/274127/9789290226383-eng.pdf).
49. Reibel F, Chauffour A, Aubry A, et al. New Insights into the Geographic Distribution of Mycobacterium leprae SNP Genotypes Determined for Isolates from Leprosy Cases Diagnosed in Metropolitan France and French Territories. PLoS Negl Trop Dis 2015;9(10):e0004141.
50. Norman F, Fanciulli C, López-Vélez R, et al. Imported and autochthonous leprosy presenting in Madrid (1989-2015): A case series and review of the literature. Travel Med Infect Dis 2016;14:331-349.
51. Prasad S, Misra R, Aggarwal A, et al. Leprosy revealed in a rheumatology clinic: a case series. Int J Rheum Dis 2013;16:129–133.
52. Baharuddin H, Taib T, Zain MM, Ch'ng S. Leprae reaction resembling rheumatologic disease as presenting feature of leprosy. Int J Rheum Dis 2016;19(10):1035-1038.
53. Ribeiro FM, Gomez VE, Shoenfeld Y, et al. Lupus and leprosy: beyond the coincidence. Immunol Res 2015;61(1-2):160-163.
54. Junior G, Elis E, Magalhães V. Application of the diagnostic criteria for systemic lupus erythematosus to patients with multibacillary leprosy. Rev Soc Bras Med Trop 2011;44:85-90.
55. Horta-Baas G, Hernandez-Cabrera MF, Arenas-Guzman R, et al. Multibacillary leprosy mimicking systemic lupus erythematosus: case report and literature review. Lupus 2015;24(10):1095–102.
56. Labuda SM, Schieffelin JS, Shaffer JG, Stryjewska BM. Hansen's Disease and Rheumatoid Arthritis Crossover of Clinical Symptoms: A Case Series of 18 Patients in the United States. Am J Trop Med Hyg 2017;97(6):1726-1730.
57. Hsieh TT, Wu YH. Leprosy mimicking lupus erythematosus. Dermatol Sin 2014:32(1):47-50.
58. Karadeniz A, Lally L, Lockshin MD, et al. Lepromatous Leprosy Mimicking Systemic Lupus Erythematosus. HSS J 2014;10(3):286-291.
59. Garg G, Gogia A, Kakar A. Leprosy: A Great Mimicking Disease. Indian J Lepr 2016;88(2):123-127
60. Kusumaningrum N, Purnamawati S, Soebono H, et al. Lepromatous leprosy mimicking systemic lupus erythematosus: a case report. Med J Indones 2019;28(1):77-1.
61. African Trypanosomiasis. Geneva: World Health Organization; 2020 (http://www.who.int/topics/trypanosomiasis_african/en, accessed 09 August 2020).
62. Meltzer E, Leshem E, Steinlauf S, et al. Human African trypanosomiasis in a traveler: diagnostic pitfalls. Am J Trop Med Hyg 2012;87(2):264-266.
63. Sudarshi D, Brown M. Human African trypanosomiasis in non-endemic countries. Clin Med 2015;15(1):70-73.
64. Guillaume MP, Hermanus N, Karmali R, et al. Specific autoantibodies of SLE, such as anti-Ku, anti-ribosome Po and anti-membrane DNA autoantibodies, in a case of human African trypanosomiasis. Rheumatology 2003 ;42(12) :1568–1569.
65. Kirrstetter M, Lerin-Lozano C, Lamprecht P, et al. Trypanosomiasis in a woman from Cameroon mimicking systemic lupus erythematosus]. Dtsch Med Wochenschr 2004;129(23):1315-1317.
66. Leavitt RY, Fauci AS, Lightfoot RW, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33(8):1101.
67. Robson JC, Grayson PC, Ponte C, DCVAS Investigators, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 2022;81(3):315-320.
68. Guntupalli L, Patel K, Faraji F, Brunworth JD. Autoimmune-related nasal septum perforation: A case report and systematic review. Allergy Rhinol 2017;8(1):40-44.
69. Montone KT. The molecular genetics of inflammatory, autoimmune, and infectious diseases of the sinonasal tract: a review. Arch Pathol Lab Med 2014;138(6):745-753.
70. Laudien M. Orphan diseases of the nose and paranasal sinuses: Pathogenesis - clinic - therapy. GMS Curr Top Otorhinolaryngol Head Neck Surg 2015;14:Doc04.
71. Sachse F, Stoll W. Nasal surgery in patients with systemic disorders. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc02.
72. Alam E, Abbas O, Moukarbel R, Khalifeh I. Cutaneous Leishmaniasis: An Overlooked Etiology of Midfacial Destructive Lesions. PLoS Negl Trop Dis 2016;10(2):e0004426.
73. Edington FL, Bacellar MO, Machado PR, et al. Anti-neutrophil cytoplasmic antibodies in leprosy. Clin Rheumatol 2007;26(2):208-210.
74. Camacho ID, Burdick A, Benjamin L, Casiano R. Chronic rhinitis: a manifestation of leprosy. Ear Nose Throat J 2011;90(9):E1-E3.
75. Kim JH, Lee OJ, Lee JJ, Park CH. Analysis of facial deformities in korean leprosy. Clin Exp Otorhinolaryngol 2013;6(2):78-81.
76. Crovetto-Martínez, R, Aguirre-Urizar JM, Torre CD, et al. Mucocutaneous leishmaniasis must be included in the differential diagnosis of midline destructive disease: Two case reports. OOOO Journal 2014;119(1):20-26.
77. Bhat R, Sharma VK, Deka RC. Otorhinolaryngologic manifestations of leprosy. Int J Dermatol 2007;46(6):600-606.
78. Martins AC, Castro JC, Moreira JS. A ten-year historic study of paranasal cavity endoscopy in patients with Leprosy. Braz J Otorhinolaryngol 2005;71(5):609-615.
79. Taheri JB, Mortazavi H, Moshfeghi M, et al. Oro-facial manifestations of 100 leprosy patients. Med Oral Patol Oral Cir Bucal. 2012;17(5):728-732.
80. Pooja VK, Vanishree M, Surekha R, et al. Evaluation of the orofacial lesions in treated leprosy patients. J Oral Maxillofac Pathol 2014;18(3):386-389.
81. Lockwood D. Recognizing Leprosy: Pointers for the Busy Rheumatologist. Rheumatology 2014;53:i12.
82. Wall EC, Watson J, Lockwood DN, et al. Epidemiology of imported cutaneous leishmaniasis at the Hospital for Tropical Diseases, London, United Kingdom: use of polymerase chain reaction to identify the species. Am J Trop Med Hyg 2012;86(1):115-8.
83. Bart A, Thiel PP, Van Gool T, et al. Imported leishmaniasis in the Netherlands from 2005 to 2012: epidemiology, diagnostic techniques and sequence-based species typing from 195 patients. Euro Surveill 2013;18(30)205-44.
84. Antunes ML, Cabral G, Araújo J, et al. Going Round in Circles with a Multisystemic Disease: A Unique Case of Parasitic Aortitis. Eur J Case Rep Intern Med 2017;4(6):000601.
85. Chauhan A, Scott DGI, Neuberger J, et al. Churg–Strauss vasculitis and ascaris infection. Ann Rheum Dis 1990;49:320–322.
86. Pandey S, Nayak R, Mehndiratta MM. Hansen's disease manifesting as acute distal symmetric microvasculitic polyneuropathy. Clin Neurol Neurosurg 2013;115(10):2223-2225.
87. Sampaio L, Silva L, Terroso G, et al. Hansen's disease mimicking a systemic vasculitis. Acta Reumatol Port 2011;36(1):61-64.
88. Sadeghinia A, Azizzadeh-Roodpishi S, Mahmoudi H, et al. A Case of Lepromatous Leprosy Clinically Masquerading as Vasculitis. Dermatol Pract Concept 2019;9(3):222-224.
89. Pawar M, Zawar V. Mid-borderline leprosy masquerading as an overlap syndrome. Rheumatology 2018 ;57(9):1686–1688.
90. Gupta L, Zanwar A, Wakhlu A, Agarwal V. Leprosy in the rheumatology clinic: an update on this great mimic. Int J Rheum Dis 2016;19(10):941–5.
91. Lee JY, Park SE, Kim SS, et al. Case of lepromatous leprosy misdiagnosed as systemic sclerosis. J Dermatol 2014;41(4):343–5.
92. Pruthi P, Munganda H, Brajpuriya S, et al. Case Report Leprosy with Atypical Skin Lesions Masquerading as Relapsing Polychondritis. Case Rep Infect Dis 2016;2016:7802423.
93. Yusuf SYM, Ismail IA, Yasin MM, et al. Isolated Bilateral Pinna Swelling: A Rare Initial Presentation of Leprosy. Open Access Maced J Med Sci 2019;7(11):1815-1817.
94. Deligny C, Arfi S. Images in clinical tropical medicine. Pseudochondritis in leprosy. Am J Trop Med Hyg 2010;83(6):1175.
95. Levy M, Bourrat E, Fila M, et al. Toxocara canis infection: Unusual trigger of systemic lupus erythematosus. Ped Intern 2015;57(4):785-788.
96. De Boysson H, et al. Vasculitis Secondary to anti-C1q Antibodies Induced By Toxocariasis. Infection 2015 ;43(6) :755-8.
97. Kotton CN. Chapter 5 - Immunocompromised travellers. Centers for Disease Control and Prevention; 2019 (https://wwwnc.cdc.gov/travel/yellowbook/2020/travelers-with-additional-considerations/immunocompromised-travelers, accessed 09 August 2020).
98. Braz AS, de Andrade CA, Da Mota LM, Lima CM. Recommendations from the Brazilian Society of Rheumatology on the diagnosis and treatment of intestinal parasitic infections in patients with autoimmune rheumatic disorders. Rev Bras Reumatol 2015;55:368-80.
99. Libman L, Barkati S. Chapter 11 – Screening asymptomatic returned travellers. Centers for Disease Control and Prevention ; 2019 (https://wwwnc.cdc.gov/travel/yellowbook/2020/posttravel-evaluation/screening-asymptomatic-returned-travelers, accessed 09 August 2020).
100. Refugee Health guidelines. Centers for Disease Control and Prevention; 2020 (https://www.cdc.gov/immigrantrefugeehealth/guidelines/refugee-guidelines.html, accessed 09 August 2020).
101. Krolewiecki A, Nutman TB. Strongyloidiasis: A Neglected Tropical Disease. Infect Dis Clin North Am 2019;33(1):135-151.
102. Requena-Méndez A, Buonfrate D, Muñoz J, et al. Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries. Am J Trop Med Hyg 2017;97(3):645-652.
103. Boggild AK, Libman M, Greenaway C, McCarthy AE. CATMAT statement on disseminated strongyloidiasis: prevention, assessment and management guidelines. Can Commun Dis Rep 2016;42:12-19
104. Agbata EN, Morton RL, Bisoffi Z, et al. Effectiveness of Screening and Treatment Approaches for Schistosomiasis and Strongyloidiasis in Newly-Arrived Migrants from Endemic Countries in the EU/EEA: A Systematic Review. Int J Environ Res Public Health 2018;16(1):11.
105. Velasco M, Gimeno-Feliú LA, Molina I, et al. Screening for Trypanosoma cruzi infection in immigrants and refugees: Systematic review and recommendations from the Spanish Society of Infectious Diseases and Clinical Microbiology. Euro Surveill 2020;25(8):1900393.
106. Salvador F, Sánchez-Montalvá A, Sulleiro E, et al. Prevalence of Chagas Disease among Solid Organ-Transplanted Patients in a Nonendemic Country. Am J Trop Med Hyg 2018;98(3):742-746.
107. Pinazo MJ, Espinosa G, Cortes-Lletget C, et al. Immunosuppression and Chagas disease: a management challenge. PLoS Negl Dis 2013;7:e1965.